DOAJ Open Access 2023

Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer

Lindor Qunaj Michael S. May Alfred I. Neugut Alfred I. Neugut Alfred I. Neugut +2 lainnya

Abstrak

KRAS G12C mutations are critical in the pathogenesis of multiple cancer types, including non-small cell lung (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and colorectal (CRC) cancers. As such, they have increasingly become a target of novel therapies in the management of these malignancies. However, the therapeutic success of KRAS G12C inhibitors to date has been far more limited in CRC and PDAC than NSCLC. In this review, we briefly summarize the biochemistry of KRAS targeting and treatment resistance, highlight differences in the epidemiology of various G12C-mutated cancers, and provide an overview of the published data on KRAS G12C inhibitors for various indications. We conclude with a summary of ongoing clinical trials in G12C-mutant CRC and a discussion of future directions in the management of this disease. KRAS G12C mutation, targeted therapies, colorectal cancer, non-small cell lung cancer, pancreatic cancer, drug development.

Topik & Kata Kunci

Neoplasms. Tumors. Oncology. Including cancer and carcinogens

Penulis (7)

Lindor Qunaj

Michael S. May

Alfred I. Neugut

Benjamin O. Herzberg

Format Sitasi

APA MLA BibTeX

Qunaj, L., May, M.S., Neugut, A.I., Neugut, A.I., Neugut, A.I., Herzberg, B.O. et al. (2023). Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer. https://doi.org/10.3389/fonc.2023.1252516

Akses Cepat

PDF tidak tersedia langsung

Cek di sumber asli →

Lihat di Sumber doi.org/10.3389/fonc.2023.1252516

Informasi Jurnal

Tahun Terbit: 2023
Sumber Database: DOAJ
DOI: 10.3389/fonc.2023.1252516
Akses: Open Access ✓